UK-based antiviral drug discovery and development company reViral has announced the appointment of Professor Raymond Schinazi to its Board as a Non-Executive Director, effective from 9 April 2014. 28 April 2014
Novartis Vaccines, the vaccination branch of Swiss drug major Novartis (NOVN: VX), has announced the appointment of Dr John Porter to the position of Medical Affairs Director for Cluster North Europe. 25 April 2014
Digital medicines company Proteus Health, have announced the expansion of the company’s executive team and board of directors with the addition of three industry leaders across consumer technology and global pharmaceuticals. 25 April 2014
China’s WuXi PharmaTech (NYSE: WX) has announced that Dr Steve Yang has joined the company as Executive Vice President and Chief Operating Officer. Edward Hu will assume new responsibilities as Chief Investment Officer and remain as Chief Financial Officer. 24 April 2014
US generic drugmaker Impax Laboratories (NASDAQ: IPXL) has announced the appointment of Frederick Wilkinson as President and Chief Executive Officer effective April 29, 2014. 24 April 2014
Japanese drugmaker Daiichi Sankyo has announced that Ken Keller will join the company as President of its Commercial operations in the United States. 23 April 2014
Swiss drug major Novartis has announced the appointment of Jeff George as Division Head of Alcon and Richard Francis as new Division Head of Sandoz. 22 April 2014
South African drugmaker Adcock Ingram has announced the appointment of Kevin Wakeford (pictured) as Chief Executive Officer, with immediate effect. 22 April 2014
The US subsidiary of Japanese drug major Astellas Pharma announced that Jeffrey Bloss has been promoted to the position of senior vice president, medical affairs Americas, Astellas Scientific and Medical Affairs (ASMA), effective April 1. Dr Bloss will serve as a member of the Astellas US management committee. 16 April 2014
New Haven Pharmaceuticals, a privately held specialty pharmaceuticals company, today announced the appointment of Larry Dillaha, to the newly-created position of Executive Vice President Operations. 2 April 2014
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024